The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Pharma; R-Pharma-US
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turningpoint Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; Jounce Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Geoffrey R. Oxnard
Honoraria - Foundation Medicine; Guardant Health; Sysmex
Consulting or Advisory Role - Abbvie; AstraZeneca; DropWorks; GRAIL; Illumina; Inivata; Janssen; LOXO; Merck; Merck; Sysmex; Takeda
Patents, Royalties, Other Intellectual Property - DFCI has a patent pending titled "Non-invasive blood-based monitoring of genomic alterations in cancer", on which I am a co-author. (Inst)
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Dwight Hall Owen
Consulting or Advisory Role - AstraZeneca; L&M Policy Research; TheMednet Org
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Palobiofarma (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Byoung Chul Cho
Stock and Other Ownership Interests - Bridgebio therapeutics; Gencurix Inc; TheraCanVac Inc
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; MOGAM Institute; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; MOGAM Institute; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Herbert H. F. Loong
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche/Genentech
Speakers' Bureau - Abbvie; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Caroline Elizabeth McCoach
Honoraria - Genentech; Novartis
Speakers' Bureau - Novartis
Research Funding - Novartis; Revolution Medicines
Travel, Accommodations, Expenses - Lilly; Loxo; Takeda
 
Jared Weiss
Stock and Other Ownership Interests - Nektar; Vesselon
Honoraria - Pfizer
Consulting or Advisory Role - abbvie; AstraZeneca; Azitra; Blueprint Medicines; Celgene; EMD Serono; G1 Therapeutics; Genentech; Inivata; Jounce Therapeutics; Lilly; Nanobiotix; Pfizer; rakuten
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Carefusion (Inst); Celgene (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
YuJung Kim
No Relationships to Disclose
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Boehringer Ingelheim; G1 Therapeutics; Genentech/Roche; Loxo; Novartis; Takeda
Research Funding - BeyondSpring Pharmaceuticals
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Hanmi; Lilly; LOXO; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - AZD; Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Haruko Daga
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst); Tolero Pharmaceuticals (Inst)
 
Oliver Gautschi
Other Relationship - Bayer (Inst)
 
Sarah Ng
Employment - Loxo
Stock and Other Ownership Interests - Loxo
 
Xin Huang
Employment - Loxo
Stock and Other Ownership Interests - Loxo
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicians Education Resources; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Ariad/Millenium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva